Corrigendum to “Protective effects of sitagliptin on myocardial injury and cardiac function in an ischemia/reperfusion rat model” [Eur J Pharmacol. 718 (1-3) (2013) 105-13](S0014299913006572)(10.1016/j.ejphar.2013.09.007);Protective effects of sitagliptin on myocardial injury and cardiac function in an ischemia/reperfusion rat model

European Journal of Pharmacology

Volumn 718, Issue 1-3, 2013, Pages 105-113

  Chang, Guanglei ^a   Zhang, Peng ^a   Ye, Lin ^a   Lu, Kai ^a   Wang, Ying ^a   Duan, Qin ^a   Zheng, Aihua ^a   Qin, Shu ^a   Zhang, Dongying ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Cardiac function; Cardiomyocyte apoptosis; DPP4 inhibitor; Ischemia reperfusion; Myocardial injury; Sitagliptin

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CASPASE 3; CREATINE KINASE MB; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUTATHIONE PEROXIDASE; LACTATE DEHYDROGENASE; MALONALDEHYDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; SITAGLIPTIN; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG TARGETING; ENZYME RELEASE; HEART FUNCTION; HEART MUSCLE CELL; HEART MUSCLE INJURY; HEART PROTECTION; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

CARDIAC FUNCTION; CARDIOMYOCYTE APOPTOSIS; DPP4 INHIBITOR; ISCHEMIA/REPERFUSION; MYOCARDIAL INJURY; SITAGLIPTIN;

ANIMALS; APOPTOSIS; BODY WEIGHT; CARDIOTONIC AGENTS; CREATINE KINASE, MB FORM; DISEASE MODELS, ANIMAL; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; GLUTATHIONE PEROXIDASE; HEART; HEART VENTRICLES; L-LACTATE DEHYDROGENASE; MALE; MALONDIALDEHYDE; MYOCYTES, CARDIAC; ORGAN SIZE; PYRAZINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLUCAGON; REPERFUSION INJURY; SUPEROXIDE DISMUTASE; TRIAZOLES;

EID: 84887100953     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2019.172876     Document Type: Erratum

References (30)

1. E. Acar, D. Ural, U. Bildirici, T. Sahin, and I. YIlmaz Diabetic cardiomyopathy Anadolu Kardiyoloji Dergis 11 2011 732 737
2. K. Ban, M.H. Noyan-Ashraf, J. Hoefer, S.S. Bolz, D.J. Drucker, and M. Husain Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways Circulation 117 2008 2340 2350
3. A. Barnett DPP4 inhibitors and their potential role in the management of type 2 diabetes International Journal of Clinical Practice 60 2006 1454 1470
4. S. Bhashyam, A.V. Fields, B. Patterson, J.M. Testani, L. Chen, Y.T. Shen, and R.P. Shannon Glucagon-like peptide-1 increases myocardial glucose uptake via p38alpha MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy Circulation: Heart Failure 3 2010 512 521
5. K. Chinda, S. Chattipakorn, and N. Chattipakorn Cardioprotective effects of incretin during ischaemia-reperfusion Diabetes and Vascular Disease Research 9 2012 256 269
6. K. Chinda, S. Palee, S. Surinkaew, M. Phornphutkul, S. Chattipakorn, and N. Chattipakorn Cardioprotectiveeffect of dipeptidyl peptidase-4 inhibitor during ischemia-reperfusion injury International Journal of Cardiology 167 2012 451 457
7. J. Doupis, and A. Veves DPP4 inhibitors: a new approach in diabetes treatment Advances in Therapy 25 2008 627 643
8. Y. Fujio, T. Nguyen, D. Wencker, R.N. Kitsis, and K. Walsh Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart Circulation 101 2000 660 667
9. A.J. Garber Novel GLP-1 receptor agonists for diabetes Expert Opinion on Investigational Drugs 21 2012 45 57
10. A.J. García-Sáez The secrets of the Bcl-2 family Cell Death and Differentiation 19 2012 1733 1740
11. R.A. Gottlieb Cell death pathways in acute ischemia/reperfusion injury Journal of Cardiovascular Pharmacology and Therapeutic 16 2011 233 238
12. B.D. Green, P.R. Flatt, and C.J. Bailey Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes Diabetes and Vascular Disease Research 3 2006 159 165
13. T. Jose, and S.E. Inzucchi Cardiovascular effects of the DPP-4 inhibitors Diabetes and Vascular Disease Research 9 2012 109 116
14. P.N. Khalil, C. Neuhof, R. Huss, M. Pollhammer, M.N. Khalil, H. Neuhof, H. Fritz, and M. Siebeck Calpain inhibition reduces infarct size and improves global hemodynamics and left ventricular contractility in a porcine;myocardial ischemia/reperfusion model European Journal of Pharmacology 528 2005 124 131
15. H.C. Ku, W.P. Chen, and M.J. Su DPP4 deficiency preserves cardiac function via GLP-1 signaling in rats subjected to myocardial ischemia/reperfusion Naunyn-Schmiedeberg's Archives of Pharmacology 384 2011 197 207
16. M. Lenski, A. Kazakov, N. Marx, M. Böhm, and U. Laufs Effects of DPP-4 inhibition on cardiac metabolism and function in mice Journal of Molecular and Cellular Cardiology 51 2011 906 918
17. C. Li, Z. Liu, J. Tian, G. Li, W. Jiang, G. Zhang, F. Chen, P. Lin, and Z. Ye Protective roles of Asperosaponin VI, a triterpenesaponin isolated from Dipsacusasper Wall on acute myocardial infarction in rats European Journal of Pharmacology 627 2010 235 241
18. D. Lorber GLP-1 receptor agonists: effects on cardiovascular risk reduction Cardiovascular Therapeutics 31 2012 238 249
19. T. Matsui, J. Tao, F. del Monte, K.H. Lee, L. Li, M. Picard, T.L. Force, T.F. Franke, R.J. Hajjar, and A. Rosenzweig Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo Circulation 104 2001 330 335
20. W. Mughal, R. Dhingra, and L.A. Kirshenbaum Striking a balance: autophagy, apoptosis, and necrosis in a normal and failing heart Current Hypertension Reports 14 2012 540 547
21. C.J. Mullonkal, and L.H. Toledo-Pereyra Akt in ischemia and reperfusion Journal of Investigative Surgery 20 2007 195 203
22. D. Mundil, A. Cameron-Vendrig, and M. Husain GLP-1 receptor agonists: a clinical perspective on cardiovascular effects Diabetes and Vascular Disease Research 9 2012 95 108
23. M.A. Nauck, N. Kleine, C. Orskov, J.J. Holst, B. Willms, and W. Creutzfeldt Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients Diabetologia 36 1993 741 744
24. P.A. Read, F.Z. Khan, P.M. Heck, S.P. Hoole, and D.P. Dutka DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease Circulation: Cardiovascular Imaging 3 2010 195 201
25. M. Sauvé, K. Ban, M.A. Momen, Y.Q. Zhou, R.M. Henkelman, M. Husain, and D.J. Drucker Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice Diabetes 59 2010 1063 1073
26. A.J. Scheen Cardiovascular effects of gliptins Nature Reviews Cancer 13 2012 73 84
27. D. Sun, J. Huang, Z. Zhang, H. Gao, J. Li, M. Shen, F. Cao, and H. Wang Luteolin limits infarct size and improves cardiac function after myocardium ischemia/reperfusion injury in diabetic rats PLoS One 7 2012 e33491
28. D. Verge, and X. Lopez Impact of GLP-1 and GLP-1 receptor agonists on cardiovascular risk factors in type 2 diabetes Current Diabetes Reviews 6 2010 191 200
29. Y. Ye, K.T. Keyes, C. Zhang, J.R. Perez-Polo, Y. Lin, and Y. Birnbaum The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA American Journal of Physiology: Heart and Circulatory Physiology 298 2010 H1454 H1465
30. M. Yin, H.H. Silljé, M. Meissner, W.H. van Gilst, and R.A. de Boer Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure Cardiovascular Diabetology 10 2011 85 94